Statins and Depression: What Is the Connection?

The bulk of the evidence points in a direction many people find surprising: statins appear to be modestly linked with a lower risk of developing depression, not a higher one. A 2025 meta-analysis of cohort studies found that statin users had roughly 14% lower odds of depression than non-users. But that population-level trend coexists with a small number of people who report real mood worsening after starting a statin, and the science behind both patterns turns out to be genuinely interesting.

What Large Studies Actually Show

Several major observational studies have tracked hundreds of thousands of people to see whether statin users develop depression at different rates. A large prospective cohort study following over 363,000 participants for about 13 years found that statin users had a roughly 13% lower risk of developing depression compared to non-users.¹ A 2025 systematic review and meta-analysis confirmed this direction, reporting significantly lower odds of depression among statin users in cohort studies.²

A Swedish national cohort study added a useful nuance: not all statins produced the same signal. Overall statin use was associated with about 5% lower adjusted odds of depression, but when the researchers looked at individual drugs, simvastatin was associated with about 7% lower odds while atorvastatin was associated with about 11% higher odds.³ That split hints at something this article returns to later: which statin you take may matter.

One particularly rigorous Swedish study used a within-individual design, comparing the same person’s depression rates during periods when they were taking a statin versus periods when they were not. This approach eliminates a lot of the confounding that plagues observational research. The result: periods on statins were associated with about 9% lower rates of depressive disorders. The same study found no significant link between statin use and suicidal behavior, anxiety, or seizures.⁴

Statins as Add-On Therapy for Existing Depression

A separate question from prevention is whether statins can help people who already have depression. Here the picture is more mixed but still leaning positive in some contexts. A meta-analysis of randomized controlled trials found that when a statin was added to an antidepressant, patients showed a moderate improvement in depression scores at both eight and twelve weeks compared to those receiving antidepressant plus placebo.⁵ An earlier meta-analysis of double-blind, placebo-controlled trials was even more optimistic, reporting a large improvement in depression scores when statins were added to standard treatment.⁶

A meta-analysis looking specifically at statins added to SSRIs found that the combination produced significantly greater reductions in standardized depression scores and also lowered C-reactive protein, a blood marker of inflammation.⁷ That inflammation finding matters, because it connects to one of the leading theories about why statins affect mood at all.

But a major caveat came from a well-designed 2023 randomized trial focused on treatment-resistant depression. In that trial, adding simvastatin to standard care produced no additional benefit for depressive symptoms compared to placebo. The difference between groups was negligible.⁸ A reasonable interpretation of the combined trial evidence: statins may boost the effect of antidepressants in people who are still somewhat responsive to treatment, but they do not appear to rescue people whose depression has already stopped responding to standard medications. Statins as a standalone treatment for depression also lack support; a review of the evidence concluded they are not effective as monotherapy but may serve as useful additions to conventional antidepressants.⁹

Why Statins Might Affect Mood at All

Statins were designed to lower cholesterol. Why would a cholesterol drug have anything to do with brain chemistry? The answer involves at least three overlapping biological pathways.

The first and most studied is inflammation. Depression is increasingly understood to involve chronic low-grade inflammation, with elevated levels of inflammatory molecules circulating in the blood and brain. Statins have well-documented anti-inflammatory properties that extend beyond their cholesterol-lowering effects. Animal studies show that simvastatin and atorvastatin can reduce depressive-like behavior by dampening brain inflammation, suppressing inflammatory signaling, and calming overactive immune cells in the brain.¹⁰ Human studies have found that statins can reduce circulating levels of several inflammatory markers linked to depression.⁷

The second pathway involves serotonin, the neurotransmitter most commonly targeted by antidepressants. Cholesterol is a structural component of brain cell membranes, and the proteins that transport serotonin are embedded in those membranes. When statins lower brain cholesterol, they can change how the serotonin transporter works, potentially mimicking some of the effects of SSRI antidepressants. Research has found that statins can boost the effects of fluoxetine (Prozac) and alter serotonin transporter activity in living organisms.¹¹

The third pathway involves a protein called BDNF, which supports the survival and growth of neurons. Low BDNF levels have been consistently linked to depression. Animal research suggests that statins can increase BDNF levels in the brain through specific signaling pathways.¹² Simvastatin in particular has been shown to upregulate BDNF in animal models, which is associated with improved cognitive and behavioral outcomes.¹³

When Statins Worsen Mood

Despite the population-level trends pointing toward a protective effect, some individuals clearly experience mood deterioration on statins. A case series documented 12 people who reported mood and behavior changes after starting a statin, including irritability, depression, violent thoughts, and suicidal ideation. These problems began after the statin was started, continued or worsened with ongoing use, resolved when the drug was stopped, and in cases where the person tried the drug again, the symptoms returned.¹⁴ That pattern of onset, resolution, and recurrence on rechallenge is strong evidence that the statin was the cause in those individuals, even though it is a small number of cases.

This creates what looks like a contradiction with the larger studies, but it is actually a familiar pattern in medicine. A drug can lower the average risk of a condition across a population while still causing that condition in a susceptible minority. Individual vulnerability likely depends on genetics, other medications, and existing mental health conditions, though the research has not yet clearly identified who is most at risk for statin-related mood problems.

One factor that complicates the picture is the nocebo effect, where expecting side effects causes people to experience them. A clever crossover trial had participants take statin tablets, placebo tablets, and no tablets during alternating months, rating their symptoms throughout. Symptom scores were significantly higher during both statin months and placebo months compared to no-tablet months, with no meaningful difference between statin and placebo. The nocebo ratio was 0.90, meaning that about 90% of the side-effect burden people attributed to the statin also showed up when they took a dummy pill.¹⁵ This does not mean every statin side effect is imagined, but it does mean that a significant proportion of the symptoms people report are driven by expectation rather than the drug’s chemistry.

Does the Type of Statin Matter

Statins come in two broad categories based on their ability to dissolve in fat. Lipophilic statins (like simvastatin, atorvastatin, and lovastatin) dissolve easily in fats and can cross from the bloodstream into the brain more readily. Hydrophilic statins (like rosuvastatin and pravastatin) dissolve in water and have a harder time reaching brain tissue. Since the proposed antidepressant mechanisms involve direct effects on brain cells, you might expect lipophilic statins to have a stronger effect on mood, for better or worse.

The evidence on this is inconsistent. A large retrospective cohort study found that lipophilic statin use was not significantly associated with a higher risk of depression compared to hydrophilic statins overall. However, when the researchers looked at individual drugs, simvastatin was associated with a modest increase in depression risk compared to hydrophilic statins.¹⁶ This finding sits uneasily alongside the Swedish national cohort study mentioned earlier, which found simvastatin associated with lower odds of depression while atorvastatin (also lipophilic) was linked to higher odds.³ The honest assessment is that we do not yet have a clear, consistent picture of which statins are better or worse for mood. The lipophilic-versus-hydrophilic distinction is theoretically plausible but has not cleanly sorted itself out in population data.

Age and the Timing of Brain Changes

Depression in older adults is often different from depression in younger people. Late-life depression is more closely tied to vascular damage and structural changes in the brain. A study of older adults in Australia and the United States found no protective effect of statins against depressive symptoms in that population. The researchers suggested that once age-related brain changes have occurred, anti-inflammatory strategies like statins may be unable to reverse the process, even if they could have helped prevent it at earlier stages.¹⁷

This fits with the broader pattern in the data. If statins protect against depression partly through anti-inflammatory effects, that protection makes more sense as prevention than as treatment of established disease, particularly in older adults whose depression may have a different underlying biology. A review of the statin-depression literature noted that although statins are commonly associated with sleep problems in the general population, no study had specifically reported sleep disturbances linked to depressive symptoms in statin users, including in older adults who are generally more prone to sleep difficulties.¹⁸

Hormonal Effects and Mood

There is another route by which statins could influence mood that gets less attention: hormones. Cholesterol is the precursor to all steroid hormones, including testosterone, estrogen, and cortisol. By lowering cholesterol, statins could theoretically reduce the raw material available for hormone production. A randomized, double-blind trial in men with high cholesterol found that 12 weeks of simvastatin produced a mild but statistically significant worsening of mood, with slight increases in somatization and depression scores. The treatment also lowered testosterone levels while increasing another hormone called DHEA, with no change in cortisol.¹⁹

This is a small study and the mood effects were described as mild, so it should not be over-weighted. But it raises the possibility that for some people, particularly men, the hormonal knock-on effects of statins could push mood in the wrong direction even as the anti-inflammatory effects push it the other way. The net outcome for any given person might depend on which of these competing mechanisms dominates.

How PCSK9 Inhibitors Compare

A recent study offered a different angle on the cholesterol-depression connection by comparing statins to a newer class of cholesterol-lowering drugs called PCSK9 inhibitors. These drugs lower cholesterol through a completely different mechanism than statins and do not have the same anti-inflammatory profile. In a matched cohort of over 35,000 patients, those on PCSK9 inhibitors developed depression at a significantly lower rate than those on statins. Over five years, about 6% of the PCSK9 inhibitor group developed depression compared to about 8% of the statin group.²⁰

This is a preprint and has not yet been peer-reviewed, so the numbers should be held lightly. But if the finding holds up, it is intriguing because it suggests that different approaches to lowering cholesterol have different relationships with depression. That in turn would argue against a simple “lower cholesterol equals mood changes” model and support the idea that the specific biochemical pathways a drug engages matter more than the cholesterol reduction itself.

What This Means If You Take a Statin

If you have been prescribed a statin and are worried about depression, the weight of the evidence is reassuring. Population studies consistently show that statin users are at equal or lower risk of depression compared to non-users. The within-individual data from Sweden, which is particularly hard to explain away with confounding, supports a genuine modest protective effect.

That said, a small number of people do experience mood changes on statins. If you notice new or worsening depression, irritability, or unusual behavioral changes after starting a statin, it is worth mentioning to your doctor rather than assuming it is unrelated. In the documented cases where statins caused mood problems, the symptoms resolved when the medication was stopped.¹⁴ Your doctor may suggest trying a different statin or monitoring the situation before deciding whether to continue.

The nocebo effect is also worth keeping in mind. If you read a list of statin side effects and then start watching for them, you are more likely to notice and attribute ordinary mood fluctuations to the drug. That is not a character flaw; it is a well-documented feature of human psychology that affects almost everyone. Being aware of it can help you evaluate your own experience more clearly.

Mitochondria and Energy

One underappreciated pathway by which statins could affect mood involves energy production at the cellular level. Statins block an enzyme early in the cholesterol production pathway, but that same pathway also produces coenzyme Q10, a molecule that plays a central role in mitochondrial energy generation. Statin use routinely lowers coenzyme Q10 levels in the blood, and some studies have shown reductions in muscle tissue as well.²¹ This depletion is best known as a possible explanation for the muscle aches that some statin users experience, but mitochondrial function also matters in the brain. Neurons are extraordinarily energy-hungry cells, and impaired mitochondrial function has been linked to depression in other research contexts. Whether statin-induced coenzyme Q10 depletion is sufficient to affect mood in practice is still unclear, but it represents another plausible mechanism running counter to the anti-inflammatory and serotonergic effects that tend to be mood-protective.

Some clinicians recommend coenzyme Q10 supplementation for statin users who experience fatigue or muscle symptoms. Whether supplementation would help with mood-related complaints specifically has not been tested in rigorous trials, but it is a low-risk intervention that addresses a documented biochemical change.

1
PubMed. Association of statin use with risk of depression and anxiety: A prospective large cohort study
2
PubMed. Possible association of statin use with the risk of depression: An up-to-date systematic review and meta-analysis
3
PubMed Central. Statin use and risk of depression: a Swedish national cohort study
4
The Lancet Psychiatry. Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study
5
PubMed Central. Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
6
PubMed. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials
7
PubMed Central. Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis
8
JAMA Network Open. Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
9
PubMed Central. The Anti-Depressant Effects of Statins in Patients With Major Depression Post-Myocardial Infarction: An Updated Review
10
PubMed Central. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry
11
PubMed Central. Serotonin Signaling through Lipid Membranes
12
PubMed. Atorvastatin inhibits neuronal apoptosis via activating cAMP/PKA/p-CREB/BDNF pathway in hypoxic-ischemic neonatal rats
13
Neuropharmacology. Simvastatin prevents β-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through α7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate
14
PubMed Central. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series
15
PubMed Central. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
16
PubMed. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study
17
PubMed Central. Association Between Statin Use and Depressive Symptoms in a Large Community‑Dwelling Older Population Living in Australia and the USA: A Cross‑Sectional Study
18
PubMed Central. Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
19
Psychoneuroendocrinology. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial
20
medRxiv. Depression Risk With PCSK9 Inhibitors Versus Statins in Hyperlipidemia
21
PubMed Central. Coenzyme q10 and statin-induced mitochondrial dysfunction